ZNF217 Gene Copy Number as a Marker of Response to Standard Therapy Drugs According to ERα Status in Breast Cancer

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Standard breast cancer (BC) biomarkers have limitations in predicting treatment response.
• The ZNF217 gene is an emerging biomarker, but its role in treatment response is unclear.
• Understanding ZNF217's role can improve therapeutic decisions for BC patients.

Purpose of the Study:

• To evaluate ZNF217 gene copy number in ERα+ and ERα- BC cell lines.
• To associate ZNF217 copy number with treatment response in these cell lines.
• To validate ZNF217's prognostic value using public BC patient datasets.

Main Methods:

• Assessed ZNF217 gene copy number and cell proliferation in ERα+ and ERα- BC cell lines.
• Treated cell lines with standard drugs to evaluate response.
• Analyzed ZNF217 copy number and patient survival data from the cBioPortal database.

Main Results:

• In ERα+ cells, ZNF217 amplification correlated with decreased proliferation under treatment.
• In ERα- cells, ZNF217 gain correlated with increased proliferation under treatment.
• ZNF217 amplification/gain in ERα+/HER2- patients predicted higher survival post-treatment.

Conclusions:

• ZNF217 amplification may indicate favorable response in ERα+ BC.
• ZNF217 gain might predict treatment resistance in ERα- BC.
• Further studies on ZNF217 are needed to optimize breast cancer treatment.